Dear Point-of-Care Insider,
Welcome to the first edition of LabPulse.com's Point-of-Care Insider, a special edition newsletter you're reading as a follower of our Point-of-Care Community. You'll receive this newsletter every few months, with the goal of keeping you updated on important developments in point-of-care diagnostics.
First up is our coverage of a recent commentary that compared the diverging approaches taken by the U.S. and South Korea to manage the COVID-19 outbreak. Spoiler alert: The U.S. does not fare well in the analysis.
Even though the first cases of infection with the SARS-CoV-2 virus appeared in each country at about the same time, the authors found that the two nations took very different paths toward managing the outbreak. And point-of-care testing played a major part in South Korea's strategy.
What else is going on in the world of point-of-care lab medicine? An Israeli company developing a new point-of-care blood test platform appointed a new chairman this month. And scientists from Massachusetts General Hospital have disclosed their work with CytoPan, a compact, automated cytometry test to study breast cells gathered with fine-needle aspiration. They believe it could serve as a less-invasive alternative to standard biopsies.
Also, learn about a rapid diagnostic test for the microorganism that causes gonorrhea -- the firm developing the test recently won $19 million as part of a challenge from the U.S. government. And another firm has raised $72 million to commercialize a finger-stick complete blood count analyzer.
Finally, read about new initiatives sponsored by the U.S. government to improve COVID-19 testing, including a $249 million program sponsored by the U.S. National Institutes of Health and an initiative by the U.S. Food and Drug Administration to foster the development of tests that can be used outside lab environments.
Get these stories and more in our Point-of-Care Community and be sure to let your colleagues know about LabPulse.com!